American Lung Association’s “State of Lung Cancer” report points to stark differences in survival, screening and treatment across states

A post-treatment blood test could inform future cancer therapy decisions, study shows

In the continuing evolution of personalized medicine, a new Yale study has found evidence to support the value of a tool that measures the presence of cancer-derived molecules in the blood of patients with lung cancer years after their treatment.

March 21, 2025

Vol.51 No.11

Clinical Roundup

American College of Radiology to form early lung cancer detection registry

The American College of Radiology Lung Cancer Screening Registry is expanding and will evolve into the Early Lung Cancer Detection Registry in late 2025.

March 14, 2025

Vol.51 No.10

Clinical Roundup

Combination therapy may overcome drug resistance in lung cancer with common KRAS mutation

Scientists at VCU Massey Comprehensive Cancer Center found that combination therapy of sotorasib (Lumakras)—an FDA-approved drug in the market—and an experimental drug called FGTI-2734, could make precision medicine more effective for patients with a highly resistant form of lung cancer.

March 14, 2025

Vol.51 No.10

Drugs & Targets

FDA grants Orphan Drug designation to rhenium obisbemeda for leptomeningeal metastases in lung cancer

FDA granted Orphan Drug designation to rhenium obisbemeda (186Re) for the treatment of leptomeningeal metastases in patients with lung cancer.

March 14, 2025

Vol.51 No.10

In Brief

IU starts mobile lung cancer screening program

The Indiana University Melvin and Bren Simon Comprehensive Cancer Center and IU Health began a mobile lung cancer screening program, which includes a 40-foot truck with a CT scanner.

March 07, 2025

Vol.51 No.09

Drugs & Targets

FDA grants priority review to Boehringer’s BI 1810631 for the treatment of HER2-mutant advanced NSCLC

FDA granted priority review to Boehringer Ingelheim’s new drug application for BI 1810631 (zongertinib) for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer whose tumors have HER2 mutations and who have received prior systemic therapy.

February 21, 2025

Vol.51 No.07

American Lung Association’s “State of Lung Cancer” report points to stark differences in survival, screening and treatment across states

YOU MAY BE INTERESTED IN

A post-treatment blood test could inform future cancer therapy decisions, study shows

American College of Radiology to form early lung cancer detection registry

Combination therapy may overcome drug resistance in lung cancer with common KRAS mutation

FDA grants Orphan Drug designation to rhenium obisbemeda for leptomeningeal metastases in lung cancer

IU starts mobile lung cancer screening program

FDA grants priority review to Boehringer’s BI 1810631 for the treatment of HER2-mutant advanced NSCLC

Renew today!

Subscriber content

Never miss an issue!

Login